ATXS · As filed with the SEC
Astria Therapeutics income statement, by quarter
The statement as Astria Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Statements of Operations · USD, except per-share amounts
| USD, except per-share amounts | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024 3 months ended Dec 31, 2024 |
|---|---|---|---|---|
| Revenue: | ||||
| Collaboration revenue | 706,000 | — | — | — |
| Operating expenses: | ||||
| Research and development | 24,149,000 | 25,945,000 | 27,786,000 | — |
| General and administrative | 10,661,000 | 9,875,000 | 9,209,000 | — |
| Total operating expenses | 34,810,000 | 35,820,000 | 36,995,000 | — |
| Loss from operations | (34,104,000) | (35,820,000) | (36,995,000) | — |
| Other income (expense): | ||||
| Interest and investment income | 2,498,000 | 2,889,000 | 3,346,000 | — |
| Other expense, net | (37,000) | (121,000) | (60,000) | — |
| Total other income, net | 2,461,000 | 2,768,000 | 3,286,000 | — |
| Net loss | (31,643,000) | (33,052,000) | (33,709,000) | — |
| Net loss per share attributable to common shareholders - basic | (0.55) | (0.57) | (0.58) | — |
| Net loss per share attributable to common shareholders - diluted | (0.55) | (0.57) | (0.58) | — |
| Weighted-average common shares outstanding used in net loss per share - basic | 58,005,928 | 58,005,312 | 58,005,312 | — |
| Weighted-average common shares outstanding used in net loss per share - diluted | 58,005,928 | 58,005,312 | 58,005,312 | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.